PAH characteristics
| All patients (n=25) | ||
|---|---|---|
| N | Value | |
| Age at first PAH detection (months) | 25 | 3 (1, 14) |
| PAH detection within 1 year after ASO | 25 | 17 (68) |
| Age at first detection (months) | 1.5 (1, 3) | |
| PAH detection more than 1 year after ASO | 25 | 8 (32) |
| Age at first detection (months) | 64 (19.5, 94.5) | |
| Age at first RHC (months) | 24 | 10 (2, 30) |
| mPAP (mm Hg) | 24 | 48 (37, 55) |
| mSAP (mm Hg) | 20 | 62 (51, 65) |
| mPAP/mSAP | 20 | 0.82 (0.71, 1.07) |
| mPCWP (mm Hg) | 24 | 10 (8, 12) |
| PVRi (WU m²) | 17 | 11.5 (8.7, 13.0) |
| PAH therapy | 25 | |
| CCB monotherapy | 1 (4) | |
| PAH-targeted monotherapy | 6 (24) | |
| PAH-targeted dual therapy | 8 (32) | |
| PAH-targeted triple therapy | 10 (40) | |
Data presented as number (percentage) or as median (IQR).
ASO, arterial switch operation; CCB, calcium channel blocker; mPAP, mean pulmonary artery pressure; mPAP/mSAP, ratio between mean pulmonary and systemic artery pressure; mPCWP, mean pulmonary capillary wedge pressure; mSAP, mean systemic artery pressure; PAH, pulmonary arterial hypertension; PVRi, indexed pulmonary vascular resistance; RHC, right heart catheterisation; WU, Wood units.